Infinity inks $488M pact on Intellikine’s PI3K portfolio

Infinity Pharmaceuticals, a 2005 Fierce 15 company, has scooped up the global development and commercialization rights to a portfolio of oral PI3K inhibitors developed by Intellikine, including one inflammatory disease program slated to begin clinical trials next year. Intellikine gets $13.5 million upfront, two years of research support, plus $475 million in development, approval and commercialization milestone payments. Intellikine is holding on to an option to convert its royalty...